Floatz logo

215 assets in Castration-Resistant Prostate Carcinoma

Therapeutic assets addressing Castration-Resistant Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Relatlimab
Castration-Resistant Prostate Carcinoma
ExelixisP1C (39)
Sl-T10
Castration-Resistant Prostate Carcinoma
SL VAXiGENP1C (39)
Tcrzeta-Cd19T-Expressing T-Lymphocytes
Castration-Resistant Prostate Carcinoma
City of Hope Medical CenterP1C (39)
Xaluritamig
Castration-Resistant Prostate Carcinoma
AmgenP1C (39)
Enhanced Autologous Psma-Car T
Castration-Resistant Prostate Carcinoma
Shanghai Changzheng HospitalEarly P1C (38)
Bms-986218
Castration-Resistant Prostate Carcinoma
Bristol-Myers SquibbP2C (33)
(1R,3R)-N<sup>1</sup>-[5-(1-Ethylpropyl)pyrazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclopentanediamine
Castration-Resistant Prostate Carcinoma
Nuvation Bio Inc.P1/2C (32)
177Lu-LNC1011
Castration-Resistant Prostate Carcinoma
Affiliated Hospital of Jiangnan UniversityN/AD (30)
Magrolimab
Castration-Resistant Prostate Carcinoma
National Cancer Institute (NCI)P1D (30)
Nanrilkefusp Alfa
Castration-Resistant Prostate Carcinoma
SOTIO Biotech AGP2D (29)
68ga-psma-0057
Castration-Resistant Prostate Carcinoma
Chengdu StarRay Therapeutics Co., LtdP1/2NR ()
amo959
Castration-Resistant Prostate Carcinoma
Novartis PharmaceuticalsP1/2NR ()
hsk46575
Castration-Resistant Prostate Carcinoma
Haisco Pharmaceutical Group Co., Ltd.P1NR ()
nox66
Castration-Resistant Prostate Carcinoma
Noxopharm LimitedP1/2NR ()
Showing 201 to 215 of 215 assets
PreviousPage 5 of 5Next